Table 2 Hazard ratio for risk of recurrence, progression, cancer-specific mortality, and all-cause mortality according to time-to-first cystoscopy from the initial transurethral resection of bladder tumor.

From: Optimal timing for the first cystoscopic follow-up using time-to-treatment initiation analysis of oncologic outcomes in primary non-muscle invasive bladder cancer

Outcome

Adjusted hazard ratio (95% CI), p-value

0–2 months

2–4 months

4–6 months

6–8 months

8–12 months

Recurrence

1.08 (0.99–1.18)

1 (Ref)

1.00 (0.93–1.07)

0.92 (0.81–1.03)

1.09 (0.95–1.26)

0.080

 

0.965

0.137

0.215

Progression

1.26 (1.07–1.49)

1 (Ref)

1.02 (0.88–1.17)

1.09 (0.86–1.37)

2.10 (1.67–2.63)

0.007

 

0.797

0.474

 < 0.001

Cancer-specific mortality

1.22 (0.99–1.49)

1 (Ref)

1.02 (0.86–1.22)

1.28 (0.98–1.66)

1.96 (1.48–2.60)

0.062

 

0.817

0.067

 < 0.001

All-cause mortality

1.18 (1.08–1.29)

1 (Ref)

1.11 (1.04–1.19)

1.16 (1.04–1.30)

1.52 (1.35–1.72)

 < 0.001

 

0.002

0.007

 < 0.001

  1. Adjusted for age, sex, diagnosis year, Charlson comorbidity index score, repeated TUR–BT, Bacillus Calmette-Guérin useage, and occurrence of upper urinary tract urothelial carcinoma.
  2. CI confidence interval, Ref reference.
Back to article page